Provention Biosciences (PRVB) Enters the Danger Zone.
Chart Looks Beautiful - But Nervous is why, we use soft and dry.
LIVE QUOTE
We'll be short and sweet. We make no prediction as for...
Top Beverage Companies for 2023 and Beyond.
Here's Our Favorite Alcohol, Non-Alcohol and Exciting Privately Held Beverage Start-Ups.
Chicago IL / Beverage News Wire / November 25, 2022 / Institutional Analyst...
Cosmos Health (COSM) and Smart for Life (SMFL) Execute Letter of Intent for Strategic...
LOI Calls for the Provision of SMFL Pan-European Access and COSM North American Access for Products and Services
MIAMI and CHICAGO, Oct. 27, 2022 (GLOBE...
Smart for Life (SMFL) Featured by New to the Street
Interviews to Air on National Television Including Bloomberg and Fox Business
MIAMI, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Smart For Life (SMFL) $0.37 Announces Initiation of Equity Analyst Coverage by Dawson James...
Initiates with “Buy” recommendation and $8 price target.
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life”...
Smart for Life (SMFL) Announces Letter of Intent to Acquire Largest Acquisition to Date.
6th Acquisition to Date is Expected to Add over $15 million of Revenue and to be Accretive to Earnings.
Stated goal of $100 million in...
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that the amended protocol is still under...
CB Scientific, Inc. (CBSC) Announces FDA 510(k) Submission.
CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event Monitor
Updated product to include significant operating improvements and material design advances over...
Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...















